XML 46 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Unaudited Interim Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 211 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Operating activities:      
Net loss $ (3,194) $ (4,108) $ (110,483)
Adjustments to reconcile net loss to net cash used in operating activities:      
Unrealized loss on derivative 2,655 3,573 (4,379)
Depreciation and amortization 0 0 1,404
Non-cash settlement of Cadherin litigation 0 0 1,187
Unrealized foreign exchange loss 0 0 36
Loss on impairment of capital assets 0 0 386
Amortization of deferred lease inducements 0 0 (412)
Non-cash severance 0 0 168
Stock-based compensation - consultants 129 0 1,202
Stock-based compensation - employees 133 0 10,464
Acquired in-process research and development 0 0 13,094
Changes in operating assets and liabilities (101) 128 (292)
Net cash used in operating activities (378) (407) (87,625)
Investing activities:      
Purchase of capital assets 0 0 (1,440)
Disposal of capital assets 0 0 115
Proceeds from sale of assets 0 0 24
Release of restricted cash 0 0 190
Restricted cash 0 0 (209)
Purchase of short-term investments 0 0 (22,148)
Redemption of short-term investments 0 0 22,791
Investment in Cadherin Biomedical Inc. 0 0 (166)
Acquired intellectual property rights 0 0 (640)
Net cash used in investing activities 0 0 (1,483)
Financing activities:      
Conversion of long-term debt to equity 0 0 68
Long-term debt repayment 0 0 (65)
Capital lease repayments 0 0 (8)
Issuance of units, net of issue costs 53 0 88,066
Registration expense 0 0 (465)
Financing expenses 0 0 (544)
Proceeds from convertible note 0 0 3,017
Other liability repayments 0 0 (87)
Security deposits received 0 0 35
Proceeds from exercise of stock options 0 0 51
Net cash provided by financing activities 53 0 90,068
Effect of exchange rate on cash and cash equivalents 0 0 378
(Decrease) Increase in cash and cash equivalents (325) (407) 1,338
Cash and cash equivalents - Beginning of period 1,663 2,303 0
Cash and cash equivalents - End of period $ 1,338 $ 1,896 $ 1,338